Low-dose lacosamide-induced atrial fibrillation: Case analysis with literature review()()

Lacosamide (LCM) is a novel antiepileptic drug (AED) approved by the FDA for adjunctive treatment of partial epilepsy with and without secondary generalization. Lacosamide dose-dependent dysrhythmias (PR-interval prolongation, AV block, and atrial fibrillation/flutter) have been reported. This case...

Descripción completa

Detalles Bibliográficos
Autores principales: Kaufman, Kenneth R., Velez, Arnaldo E., Wong, Stephen, Mani, Ram
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2012
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4150593/
https://www.ncbi.nlm.nih.gov/pubmed/25688049
http://dx.doi.org/10.1016/j.ebcr.2012.10.006
Descripción
Sumario:Lacosamide (LCM) is a novel antiepileptic drug (AED) approved by the FDA for adjunctive treatment of partial epilepsy with and without secondary generalization. Lacosamide dose-dependent dysrhythmias (PR-interval prolongation, AV block, and atrial fibrillation/flutter) have been reported. This case represents the first instance of LCM-induced atrial fibrillation following a low loading dose (200 mg). Risk factors for atrial fibrillation are addressed and discussed in the context of this case. Full cardiac history is recommended prior to patients being initiated on LCM. Cardiac monitoring may be required for at-risk patients on LCM. Clinicians need to be cognizant of this potential adverse effect.

Ejemplares similares